Progressive Myoclonic Epilepsy

Gene: EPM2A

Green List (high evidence)

EPM2A (EPM2A, laforin glucan phosphatase)
EnsemblGeneIds (GRCh38): ENSG00000112425
EnsemblGeneIds (GRCh37): ENSG00000112425
OMIM: 607566, ClinGen, DECIPHER
EPM2A is in 13 panels

2 reviews

Zornitza Stark (Victorian Clinical Genetics Services)

Green List (high evidence)

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Epilepsy, progressive myoclonic 2A (Lafora) MIM#254780

Noor Al-Ali (Other)

Green List (high evidence)

Variants in the EPM2A gene are well established to be associated with progressive myoclonic epilepsy (PME), known as Lafora disease (myoclonic epilepsy of Lafora type 1), which is a rare autosomal recessive PME. The age of disease onset is typically in childhood or adolescence (4–17 years). Most patients survive 5–10 years after disease onset. Initial symptoms can include headache, difficulties with schoolwork, myoclonic jerks, generalized seizures, and visual hallucinations. Most pathogenic mutations in EPM2A, including nonsense mutations, frameshift insertions/deletions, and splice-site variants, lead to truncated or non-functional laforin protein.
- Most pathogenic mutations in EPM2A, including nonsense mutations, frameshift insertions/deletions, and splice-site variants, lead to truncated or non-functional laforin protein.
Created: 20 Nov 2025, 12:26 a.m. | Last Modified: 20 Nov 2025, 12:26 a.m.
Panel Version: 0.22

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Progressive loss of vision; photosensitivity; hepatic failure (not common); progressive myoclonic epilepsy; generalized tonic-clonic seizures; absence seizures; simple partial occipital seizures; simple partial seizures with secondary generalization; myoclonus; ataxia; progressive dementia; neurological deterioration; loss of ambulation; intracellular PAS-positive polyglucosan inclusion bodies (“Lafora bodies”); intracellular PAS-positive polyglucosan inclusion bodies (“Lafora bodies”) can be found in various tissues (brain, liver, muscle, heart, skin).

Publications

Mode of pathogenicity
Loss-of-function variants (as defined in pop up message) DO NOT cause this phenotype - please provide details in the comments

History Filter Activity

21 Nov 2025, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services)

Gene: epm2a has been classified as Green List (High Evidence).

21 Nov 2025, Gel status: 3

Set publications

Zornitza Stark (Victorian Clinical Genetics Services)

Publications for gene: EPM2A were set to

9 Jan 2020, Gel status: 3

Created, Added New Source, Set mode of inheritance, Set Phenotypes

Bryony Thompson (Royal Melbourne Hospital)

gene: EPM2A was added gene: EPM2A was added to Progressive Myoclonic Epilepsy_RMH. Sources: Expert Review Green,Royal Melbourne Hospital Mode of inheritance for gene: EPM2A was set to BIALLELIC, autosomal or pseudoautosomal Phenotypes for gene: EPM2A were set to Epilepsy, progressive myoclonic 2A (Lafora) 254780